This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Staar Surgical (STAA) and Elanco Animal Health (ELAN)

Tipranks - Tipranks - Thu Aug 6, 11:34AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD), Staar Surgical (STAA) and Elanco Animal Health (ELAN) with bullish sentiments.

Claim 55% Off TipRanks

Gilead Sciences (GILD)

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences yesterday and set a price target of $160.00. The company’s shares closed last Wednesday at $130.66.

According to TipRanks.com, Schott is a 4-star analyst with an average return of 5.7% and a 58.3% success rate. Schott covers the Healthcare sector, focusing on stocks such as Elanco Animal Health, Bristol-Myers Squibb, and Teva Pharmaceutical. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gilead Sciences with a $159.00 average price target, which is a 16.9% upside from current levels. In a report issued on July 22, Bernstein also maintained a Buy rating on the stock with a $160.00 price target.

See the top stocks recommended by analysts >>

Staar Surgical (STAA)

In a report released yesterday, John Young CFA from Canaccord Genuity maintained a Buy rating on Staar Surgical, with a price target of $32.00. The company’s shares closed last Wednesday at $23.37.

According to TipRanks.com, CFA is a 3-star analyst with an average return of 4.2% and a 56.7% success rate. CFA covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, AngioDynamics, and Pulmonx. ;'>

Currently, the analyst consensus on Staar Surgical is a Hold with an average price target of $29.71, a 24.9% upside from current levels. In a report issued on July 20, Wedbush also reiterated a Buy rating on the stock with a $40.00 price target.

Elanco Animal Health (ELAN)

William Blair analyst Brandon Vazquez maintained a Buy rating on Elanco Animal Health today. The company’s shares closed last Wednesday at $26.26.

According to TipRanks.com, Vazquez has 0 stars on 0-5 stars ranking scale with an average return of -4.0% and a 42.5% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Irhythm Technologies, and Edwards Lifesciences. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Elanco Animal Health with a $30.14 average price target, an 11.3% upside from current levels. In a report released today, TipRanks – PerPlexity also upgraded the stock to Buy with a $29.00 price target.

Read More on GILD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).